"With a strong management team in place and the addition of resources from our recent PDL funding, AxoGen is well positioned to drive growth in the peripheral nerve repair market.” Karen Zaderej, AxoGen CEO
Alachua, FL (PRWEB) March 05, 2013
AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today the appointment of Shawn McCarrey to the position of Senior Vice President of Sales, effective immediately. In this role, Mr. McCarrey will participate in the implementation of the Company’s strategic growth initiatives and will lead AxoGen’s sales organization in the United States.
“We are now transitioning into the next phase of the Company’s growth, moving from early adopters to broad usage in surgical peripheral nerve repair,” said Karen Zaderej, Chief Executive Officer of AxoGen. “Shawn’s many years of experience and strong track record of success growing sales of early stage medical technologies will enhance AxoGen’s capabilities and accelerate adoption. With a strong management team in place and the addition of resources from our recent PDL funding, we are well positioned to drive growth in the peripheral nerve repair market.”
Mr. McCarrey brings to AxoGen more than 15 years of experience as a national medical device sales executive. He most recently served as Executive Vice President of North American Cardiovascular Sales at Bayer Interventional/MEDRAD Interventional. From 1998 through 2009, Mr. McCarrey was rapidly promoted through the executive ranks at Possis Medical, an early commercial stage cardio- and peripheral-vascular company ultimately acquired by MEDRAD Interventional, culminating with his appointment as EVP of Worldwide Sales & Marketing. Earlier in his career, Mr. McCarrey served in sales and sales leadership roles in the Davol and USCI divisions of C.R. Bard.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa EMC product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.